Menu
$2,500.00
This prior art search report presents the mappings of the various elements of claim of 1 of U.S. Patent No. 11,149,278 (‘278 patent), titled “Artificial nucleic acid molecules for improved protein expression”, filed by CureVac AG on December 11, 2015, following the patent’s subsequent publication on October 19, 2021.
The patent claims an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, a vector comprising the artificial nucleic acid molecule, a cell comprising the artificial nucleic acid molecule or the vector, a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector, and a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit, or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
This preliminary search report includes the following:
Disclaimer
This ParolaPRIME™ report is not legal advice. The suggested correspondences between the features disclosed in the patent-at-issue and those disclosed in each reference reflect what Parola Analytics believes are technical similarities between those respective sets of features. Parola Analytics makes no representation concerning any legal status or effect that may arise from documents mentioned in this report, such as the validity of any apparent priority date or the assertability of any document as prior art against a patent. You should independently obtain legal counsel before attempting to rely on any portion of this report in a legal proceeding.
The references presented in this report are only preliminary and do not represent results from an exhaustive search. For the full report, request a quote.
Questions? Read our Terms and Conditions, FAQs or contact us.
Services
Links
Sign up to receive first access to our reports, the latest patent news, and other updates —
all delivered to your inbox.
Sign up now to receive monthly patent news, analysis and free insight reports.
We don’t spam, we promise.
